Top broker says buy CSL shares right now for 36% upside

The ASX 200 healthcare blue chip fell to a new 52-week low of $244.37 in early trading on Tuesday.

| More on:
A hipster-looking man with bushy beard and multiple arm tattoos sits on the floor against a sofa reading a tablet with his hand on his chin as though he is deep in thought.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Limited (ASX: CSL) shares fell to a new 52-week low of $244.37 apiece in early trading on Tuesday.

The ASX 200 healthcare giant is currently trading at $248.93 a share, up 1.04%.

The S&P/ASX 200 Index (ASX: XJO) is down 1.32% at the time of writing.

One top broker says CSL is ripe for buying, with 36% upside potential over the next 12 months.

Broker backs CSL shares for major upside over next year

Top broker Morgan Stanley says CSL can go 36% higher over the next 12 months.

The broker has an overweight rating on the healthcare stock and a $334 price target.

In The Australian today, Morgan Stanley analyst Sean Laaman says:

If EPS momentum can be further enhanced through PBM execution, our valuation and price target may prove conservative.

On the back of PBM execution/articulation, the perceived risk regarding Injectafer generics competition may diminish.

Laaman notes that CSL shares have underperformed the market in recent times.

In the year to date, CSL stock has fallen 13% while the ASX 200 has fallen 0.12%.

The reasons for this are "now well understood".

He explains:

We think this is due to recovery to pre-pandemic plasma GM in FY26-FY28 has been slower than we anticipated, FcRn disruption in CIDP possible in FY25, and generic competition nears for V4's Injectafer in Europe.

Morgans is also backing CSL shares for significant share price growth.

As my Fool colleague James reports, Morgans has CSL on its 'best ideas' list.

The broker has an add rating on CSL and a $328.28 share price target.

Morgans says:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Motley Fool contributor Bronwyn Allen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no positions in any of the companies mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on 52-Week Lows

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Materials Shares

Core Lithium share price hits a multi-year low: Will the tide change soon?

Are analysts now seeing value emerge from the lithium miner's shares?

Read more »

Red arrow going down on a stock market table which symbolises a falling share price.
52-Week Lows

2 ASX shares to buy that are at 52-week lows

Goldman Sachs thinks these beaten down shares are buys.

Read more »

A group of six young people doing the limbo on a beach, indicating oversold shares that can not go any lower.
52-Week Lows

Core Lithium share price dives another 12%. How low can it go?

Core Lithium has been playing a game of limbo with investors in 2024...

Read more »

Man on a laptop thinking.
52-Week Lows

2 ASX shares to buy that are near 52-week lows

Analysts think these beaten-down shares could be top buys.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
52-Week Lows

3 ASX 300 shares hitting new 52-week lows: Are they cheap buys?

What's sending these shares down to new lows today?

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Materials Shares

Why did this ASX All Ords stock just crash 24%?

What is weighing down this lithium stock today? Let's find out.

Read more »

A businesswoman gets angry, shaking her fist at her computer.
52-Week Lows

3 ASX shares at 52-week lows or worse

Times have been hard for owners of these shares.

Read more »

Blue chips with stock written on them.
52-Week Lows

These 3 ASX blue-chip shares just hit multi-year lows. Am I buying?

Here's what I'd do with these battered blue-chip shares...

Read more »